ProteEx Acquired by Power3
The Woodlands, Texas-based start-up ProteEx has been acquired by Power3 Medical Products in exchange for 15 million shares of Power3 common stock, Power3 said today. ProteEx, previously known as Advanced Bio/Chem, develops biomarkers for breast cancer.
Ira Goldknopf, president and chief operating officer of ProteEx, will continue to develop ProteEx’s technology and will now serve as chief scientific officer of the company. The company will continue its R&D activities at Power3’s new laboratory facilities.
Agilent Prevails in Patent Dispute with UC Over AP-MALDI
Agilent Technologies declared victory this week in a six-year-old patent interference with the University of California over who invented AP-MALDI technology.
The company announced that the US Patent and Trademark Office’s Board of Patent Appeals and Interferences had agreed on Feb. 19 to revoke US Patent No. 5,965,884, entitled “Atmospheric pressure matrix assisted laser desorption,” held since 1999 by the University of California, for the invention of AP-MALDI by Victor Laiko and Al Burlingame at UC San Francisco. Christina Maehr, spokeswoman for Agilent, told ProteoMonitor that Agilent expects to be awarded the patent “in the next couple of months,” depending on “how quickly the patent office moves along.”
Agilent and UC both applied for AP-MALDI patents in 1998, but the patent was awarded to UC, which filed the application first. The USPTO then declared an interference between the UC patent and Agilent’s application due to the closeness of their claims. Maehr said that the USPTO board made the decision to reassign the patent to Agilent based on evidence that, although UC filed first, Agilent actually invented the technology first. UC will continue to hold international patents for AP-MALDI.
Agilent sells an AP-MALDI source with an interface to its ion trap mass specs, in collaboration with Burtonsville, Md.-based MassTech. Laiko, one of the UC inventors, now works at MassTech. Agilent has been indirectly paying licensing fees to UC through MassTech, but those payments will cease once the patent is reassigned to Agilent, Maehr said. Vladimir Doroshensky of MassTech told ProteoMonitor that the patent decision would not affect MassTech. “We will still pay fees for the international patent to UC San Francisco, and now we will pay for the US patent to Agilent,” he said.
HBPP Picks Bruker’s Software as Standard
Bruker Daltonics announced this week that the HUPO Brain Proteome Project has decided to adopt the company’s ProteinScape as its standard workflow and database software suite.
Bruker said that the decision to adopt ProteinScape as the common software platform was made at the HBPP workshop held in Paris in April (see PM 4-30-04) based on a proposal from the HBPP bioinformatics subcommittee. ProteinScape was co-developed by Bruker and Dortmund, Germany-based Protagen, and is exclusively distributed by Bruker. Bruker has attended HBPP’s workshops in the past (see PM 9-12-03).
“While we are still working on community standards for proteomics in the HUPO Proteomics Standards Initiative, we have here already a software solution with ProteinScape that will be compatible with HUPO PSI and is already usable at this early time point of the HBPP project,” Rolf Apweiler, chair of the bioinformatics subcommittee, said in a statement.